Skip to main content

Table 1 Species drug combinations tested and MIC breakpoints according to DIN 2004 and EUCAST 2.0

From: Impact of minimal inhibitory concentration breakpoints on local cumulative bacterial susceptibility data and antibiotic consumption

 

MIC breakpoints (μg/ml)

 

DIN

EUCAST

Drug

S

I

R

S

I

R

Enterobacteriaceae

      

 pip./taz.

≤4

8-32

>32

≤8

16

>16

 cefotaxime

≤2

4-8

>8

≤1

2

>2

 imipenema

≤2

4

>4

≤2

4-8

>8

 ciprofloxacin

≤1

2

>2

≤0.5

1

>1

 gentamicin

≤1

2-4

>4

≤2

4

>4

Pseudomonas aeruginosa

      

 piperacillin

≤4

8-32

>32

≤16

>16

 ceftazidime

≤4

8-16

>16

≤8

>8

 imipenem

≤2

4

>4

≤4

8

>8

 meropenem

≤2

4-8

>8

≤2

4-8

>8

 ciprofloxacin

≤1

2

>2

≤0.5

1

>1

 gentamicin

≤1

2-4

>4

≤4

>4

Stenotrophomonas maltophilia

      

 trim./sulfam.

≤16

32-64

>64

≤4

>4

 Acinetobacter baumanii

      

 imipenem

≤2

4

>4

≤2

4-8

>8

 meropenem

≤2

4-8

>8

≤2

4-8

>8

 ciprofloxacin

≤1

2

>2

≤1

>1

 gentamicin

≤1

2-4

>4

≤4

>4

Enterococcus spp.

      

 ampicillin

≤2

4-8

>8

≤4

8

>8

 vancomycin

≤4

8

>8

≤4

>4

 teicoplanin

≤2

>2

 linezolid

≤4

>4

Staphylococcus spp.

      

 oxacillinb

≤1

>1

≤2

>2

 oxacillinc

≤1

>1

≤0.25

>0.25

 vancomycinb

≤4

8

>8

≤2

>2

 vancomycinc

≤4

8

>8

≤4

>4

 teicoplaninb

≤2

>2

 teicoplaninc

≤4

>4

 linezolid

≤4

>4

 rifampicin

≤0.06

>0.5

 clindamycin

≤1

2-4

>4

≤0.25

0.5

>0.5

  1. aProteus, Morganella, and Providencia spp. were tested against meropenem, bbreakpoints for S. aureus, cbreakpoints for coagulase-negative staphylococci, “─” no data.